BACKGROUND: Inflammatory breast cancer (IBC) often affects women at a relatively young age. To the authors' knowledge, the rate of BRCA variants among patients with IBC is not known. To determine the association between BRCA status and IBC, the authors evaluated its rate and compared the clinicopathologic characteristics of patients with IBC with those of patients with other breast cancers (non-IBC). METHODS: Patients who presented at the study institution's cancer genetics program and who underwent BRCA genetic testing were included in the current study. The authors compared clinicopathologic data between patients with IBC and those with non-IBC using propensity score matching to identify predictors. RESULTS: A total of 1789 patients who underwent BRCA genetic testing (1684 with non-IBC and 105 with IBC) were included. BRCA pathogenic variants were found in 27.3% of patients with non-IBC and 18.1% of patients with IBC (P 5.0384). After propensity score matching, there were no significant differences noted between patients with IBC and those with non-IBC, including the rate of BRCA pathogenic variants (P 5.5485). However, a subgroup analysis of the 479 patients with BRCA pathogenic variants demonstrated that patients with IBC (19 patients) were diagnosed at significantly younger ages compared with patients with non-IBC (P 5.0244). CONCLUSIONS: There was no clear association observed between BRCA pathogenic variants and IBC. However, among patients who tested positive for BRCA pathogenic variants, those with IBC were younger at the time of diagnosis compared with those with non-IBC breast cancers. These results confirm that genetic testing is important for patients with IBC who meet the current clinical criteria for genetic testing in breast cancer. Cancer 2018;124:466-74.
INTRODUCTION
Inflammatory breast cancer (IBC) is an aggressive subset of breast cancer comprising approximately 1% to 6% of all breast cancers diagnosed annually in the United States. 1 IBC is characterized by a young age at the time of diagnosis, aggressive tumor features such as high nuclear grade, human epidermal growth factor receptor 2 (HER2)/neu receptor amplification, triple receptor negativity (estrogen receptor [ER] , progesterone receptor [PR] , and HER2 negativity), high metastatic potential, and poor overall survival compared with breast cancers other than IBC (non-IBC). [1] [2] [3] To the best of our knowledge, the etiology of this rapidly progressive cancer remains poorly understood. Although the term "inflammatory breast cancer" is derived from its distinctive clinical appearance, current evidence suggests that inflammation plays a central role in IBC tumor formation as well. 4 Epidemiologic studies have suggested that several risk factors may be associated with the development of IBC, including younger age at menarche, younger age at first live birth, African American race/ethnicity, higher body mass index, and lower socioeconomic status. [5] [6] [7] An unexamined potential contributor to the development of IBC is the presence of pathogenic variants in the tumor suppressor genes BRCA1 and BRCA2, which generally are associated with an up to 87% lifetime risk of developing breast cancer. 8, 9 The current National Comprehensive Cancer Network (NCCN) guidelines recommend that women diagnosed with breast cancer at age 45 years, with triple-negative breast cancer (TNBC) at age 60 years, or with 2 primary breast cancers with the first diagnosis at age 50 years be tested for pathogenic gene variants in the BRCA1 and BRCA2 genes. Similarly, personal and family histories of breast, ovarian, prostate, and pancreatic cancers are associated with hereditary breast and ovarian cancer syndrome, which is caused by BRCA1 and BRCA2 pathogenic variants.
The characteristics shared between IBC and patients with BRCA mutations, including younger age at diagnosis and increased likelihood of TNBC, suggest that IBC could be associated with BRCA mutations. However, whether BRCA pathogenic variants play a role in the development of IBC currently is unknown. To the best of our knowledge, there is scant literature examining the association between IBC and BRCA pathogenic variants, including only 1 case report. 11 To determine whether BRCA pathogenic variants are associated with IBC, 1, 5 we compared the rate of BRCA mutations and other clinicopathologic characteristics between patients with IBC and patients with non-IBC who underwent BRCA genetic testing.
MATERIALS AND METHODS
Female patients who presented to the Clinical Cancer Genetics program at The University of Texas MD Anderson Cancer Center (MDACC) in Houston and underwent genetic testing for BRCA1 and BRCA2 were retrospectively evaluated for this study. All patients were either self-referred or were referred by a physician to the program on the basis of their age at the time of their breast cancer diagnosis (50 years) and/or their family history of breast or ovarian cancer. The institutional referral guidelines were based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) from 2014. 10 
Data Collection
Data collection began on February 19, 2004, and ended on December 18, 2014. Patients were identified from prospectively maintained research databases, and their characteristics were obtained after institutional review board approval at The University of Texas MD Anderson Cancer Center. Genetic test results from 1996 to 2014 were identified and only patients with known BRCA results were included.
Patients without an uninformative BRCA variant result were excluded (44 patients, 43 of whom had non-IBC and 1 with IBC). One patient with pathogenic variants in both BRCA1 and BRCA2 (non-IBC) also was excluded because she could be not be categorized by a single gene. Last, 1 patient was excluded whose results we could not confirm (non-IBC). Therefore, a total of 1789 patients remained for analysis (1684 with non-IBC and 105 with IBC).
All patients in the current study were cared for by a multidisciplinary team comprised of a breast medical oncologist, a surgeon, and a radiation oncologist. A clinical diagnosis of IBC was defined according to the criteria outlined in the seventh edition of the American Joint Committee on Cancer staging manual and the recommendations of an expert panel on IBC. 12, 13 All pathologic specimens were reviewed by a dedicated breast pathologist at MDACC, and all patients underwent routine staging workup. HER2, ER, and PR status were determined according to the American Society of Clinical Oncology/ College of American Pathologists recommendations. [12] [13] [14] Family history was obtained from patient reports provided during a genetic counseling session and the collection of a 3-generation pedigree or from the IBC registry questionnaire.
Statistical Analysis
Patient demographic and clinical characteristics were summarized and compared between the non-IBC and IBC groups, which included all patients in the study, and between the non-IBC and IBC groups among patients with BRCA pathogenic variants. In addition to BRCA variant status, the variables of interest were age at the time of first diagnosis; race/ethnicity; genetic test results; family history of breast cancer and/or ovarian cancer; histopathologic features of tumors such as ER, PR, and HER2 status; and Ashkenazi Jewish heritage. In a supplemental analysis, IBC patients identified from the High-Risk Breast registry and who were referred for genetic testing were compared with an additional sample from the IBC registry of patients with IBC who were not referred for genetic testing. The factors potentially associated with genetic test referral among patients with IBC were investigated using univariable and multivariable logistic regression analysis. The mean, standard deviation, median, and range were presented for continuous variables, and the frequency and percentage were presented for categorical variables. The 2-sample Student t test or Wilcoxon rank sum test was used to compare continuous variables, and the chi-square test or Fisher exact test was used to compare categorical variables.
Because the current study sample was limited by the lower numbers of patients in the IBC group compared with the non-IBC group, we performed a propensity score matching analysis to allow for a more balanced comparison. The IBC propensity score, defined as the probability of being diagnosed with IBC based on observed patient characteristics, was obtained using logistic regression with covariates. The covariates included having a first-degree relative with breast cancer, having any relative with breast cancer, tumor marker status (ER, PR, and HER2 status), age at the time of first cancer diagnosis, and time from the first cancer diagnosis to genetic testing. For each patient with IBC, 1 non-IBC patient with a similar propensity score was selected as a propensity-matched control. Conditional logistic regression analyses with BRCA pathogenic variants as a response variable were performed for the patients with IBC and non-IBC patients selected by propensity matching to assess the significance of each variable on the odds of having BRCA pathogenic variants.
Univariable and multivariable logistic regression analyses were used to compare the rates of BRCA pathogenic variants between patients with and without IBC. These analyses included scenarios without adjustment for covariates, with adjustment for covariates, with adjustment for covariates and propensity scores, and with stratification by propensity scores. A P value < .05 indicated statistical significance. SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina) was used for data analysis.
RESULTS
The final analysis included a total of 1789 female patients who underwent genetic testing: 1684 patients with non-IBC and 105 patients with IBC. Table 1 summarizes their demographic and clinicopathological characteristics. Patients with IBC and non-IBC patients were found to be similar with regard to age at the time of diagnosis and age at the time of genetic testing. However, the time from diagnosis to genetic testing was found to be significantly shorter for patients in the IBC group. The percentage of patients with a first-degree relative with When the same covariates and the propensity scores were adjusted for, the association between IBC status and BRCA pathogenic variant status still was not found to be significant (OR, 0.634; 95% CI, 0.343-1.169 [P 5 .1444]). In the propensity score-matched analysis (Table 2) , in which the IBC and non-IBC groups were matched for significant predictors of IBC, no statistically significant differences were detected between matched patients with IBC and those with non-IBC in any of the variables, including rate of BRCA pathogenic variant positivity (P 5 .5485).
We next performed conditional logistic regression analysis with the presence of BRCA pathogenic variants as a response variable (Table 3 ) using the propensity scorematched pairs described above. HER2 negativity (P 5 .0281) and a diagnosis of TNBC (P 5 .0155) were the only variables found to be significantly associated with the presence of BRCA pathogenic variants.
However, in an age distribution analysis, it was noted that for every 1-year decrease in age at diagnosis, patients with IBC were found to have an 8% increase in the odds of having a BRCA pathogenic variant (P 5 .0075). Therefore, among patients with IBC, BRCA pathogenic variants were most likely to occur in younger age groups (P 5 .0096) (Fig. 1) .
In the subgroup analysis of patients with BRCA pathogenic variants (479 patients), we compared clinical characteristics between patients with IBC (19 patients) and non-IBC patients (460 patients) ( Table 4) . Among these patients, those with IBC were diagnosed at significantly younger ages compared with those with non-IBC (mean 6 standard deviation: 36.6 6 8.2 years vs 41.5 6 9.4 years; P 5 .0244). The patients with and without IBC demonstrated a similar difference in age at the time of genetic testing (P 5 .0387). Patients with BRCA pathogenic variants who had IBC were less likely to have first-degree relatives with breast cancer compared with those with non-IBC (P 5 .0111).
In the supplementary analysis of referral patterns (see Supporting Information Table 1A) among patients with IBC, we compared family history and age at diagnosis between patients who were referred for genetic testing (105 patients) and patients who were not referred for A relationship between BRCA pathogenic variants and younger age was observed in the distribution of the BRCA status rate across age groups. BRCA pathogenic variants were most likely to occur in younger age groups.
genetic testing (162 patients). As expected, patients who were referred for genetic testing had significantly higher rates of a family history of breast cancer (P<.0002) and of a family history of ovarian cancer (P<.0013) compared with those who were not referred. In addition, younger age was found to be significantly associated with referral for genetic testing (P<.0001). Among patients aged > 45 years at the time of diagnosis, approximately 77% were not referred for testing, whereas among those who were aged 45 years at the time of diagnosis, approximately 38% were referred for testing (P<.0001). These associations remained statistically significant in a multivariable logistic regression analysis (P 5 .0025 for a family history of breast cancer and P 5 .0094 for a family history of ovarian cancer) (see Supporting Information Table 1B) .
DISCUSSION
In the current study, no association was noted between BRCA pathogenic variants and IBC. However, those patients with IBC were younger at the time of diagnosis compared with those with non-IBC, suggesting that IBC has a younger onset in individuals with BRCA pathogenic variants. Genetic testing should continue to be made available to those who meet current clinical testing criteria for genetic testing. We found that 18.1% of the patients with IBC and 27.3% of the patients with non-IBC had BRCA pathogenic variants (P 5 .0384). However, after adjustment for covariates in a multivariable logistic regression model and after matching for predictors of IBC in a propensity score analysis, no significant association between IBC status and BRCA variant status remained. The absence of a statistically significant difference in the percentage of individuals with germline BRCA pathogenic variants between patients with IBC and non-IBC patients does not necessarily suggest an absence of an association between BRCA pathogenic variants and IBC; these BRCA variant rates may instead reflect the distribution of important predictors such as breast cancer subtype, which is known to be strongly associated with BRCA pathogenic variants.
15
A relationship between BRCA pathogenic variants and IBC is supported by the results of the subgroup analysis of the patients with pathogenic variants in BRCA. Among these patients, those with IBC were significantly younger at the time of diagnosis compared with those with non-IBC (P 5 .0244). In addition, there was a 9% increase in the odds of having a BRCA pathogenic variant for every 1-year decrease in age at the time of diagnosis (P 5 .0075) despite the fact that the IBC and non-IBC groups had similar median ages at the time of diagnosis at both the descriptive level and after propensity score matching. It is important to note that this relationship between BRCA pathogenic variants and younger age also was observed in the comparison of IBC with BRCA pathogenic variants with BRCA-negative IBC (data not shown) and in the distribution of BRCA status rate across age groups (P 5 .0096) (Fig. 1) .
A similar association between IBC and BRCA pathogenic variant status previously was suggested in a case report that described a mother and daughter who both were diagnosed with IBC. 11 The proband was diagnosed at the age of 40 years and found to have a pathogenic variant in BRCA2. The patient's mother had been diagnosed and had died at the age of 35 years. The patient's tumor was hormone receptor positive and HER2 negative, with biopsy confirming a metastasis in the right paratracheal lymph nodes. Her personal history of early-onset invasive breast cancer and a family history of breast cancer warranted genetic counseling. To the best of our knowledge, there are no other reports describing pathogenic variants in BRCA concomitant with an IBC diagnosis.
Previous studies have suggested an association between a family history of breast cancer and a diagnosis of IBC. In a small case-comparison study conducted at MDACC, Chang et al observed that approximately 13% of patients with IBC but only 8% of patients with non-IBC reported a positive family history of breast cancer, although the difference was not statistically significant. 16 A case-comparison study conducted in Pakistan found that 20% of women with IBC but only 5% of women with non-IBC had a family history of breast cancer (P<.0002). 17 However, the degree of relativity to the IBC patients was not defined, nor was the ovarian cancer rate explored in that study. More recently, a study from the Breast Cancer Surveillance Consortium examining 617 IBC cases found that the presence of a family history of breast cancer was associated with an increased risk of developing IBC that was similar to that of developing non-IBC 7 ; however, that study investigated only the presence of female first-degree relatives with breast cancer among patients with IBC compared with those with non-IBC.
In the current study, the percentage of patients with a first-degree relative with breast cancer was significantly higher in the non-IBC group compared with the IBC group (37.8% vs 17.3%; P<.0001). However, the IBC and non-IBC groups had similar rates of all relatives with breast cancer and of relatives with other cancers. Similarly, among patients with BRCA pathogenic variants, patients with non-IBC had a higher rate of first-degree relatives with breast cancer compared with patients with IBC (50.8% vs 21.1%; P 5 .0111). These differences were lost at the time of propensity score matched analysis.
Despite previous reports that demonstrated that a higher percentage of TNBC tumors are associated with IBC compared with non-IBC tumors, the percentage of patients with TNBC in the current study was similar between the IBC and non-IBC groups, most likely reflecting the selection criteria for genetic testing. The association between TNBC and BRCA pathogenic variants was confirmed by conditional logistic regression analysis (P 5 .0155) ( Table 3) and was similar to those previously published. 15 The current study has several limitations, including its retrospective nature, the small number of patients with IBC, and the fact that it was conducted at a single institution. Moreover, the cohort examined herein was a highly selected group of patients who were referred for genetic counseling. Furthermore, the referral guidelines (institutional guidelines and NCCN guidelines 10 were based on those from 2014 and earlier; both sets of guidelines have since been updated to include referral/testing recommendations for individuals with family histories of pancreatic and prostate cancers and to address low/moderately penetrant genes commonly included in panel testing (NCCN guidelines 2017). 10 These limitations are due in part to the rarity of IBC and in particular of IBC with the presence of BRCA pathogenic variants. Perhaps the aggressive nature and rapid progression of IBC have played a role in the lack of referrals for genetic consultations noted in the past; however, this theory cannot be determined within the parameters of the current study. A Original Article supplementary analysis comparing patterns of referral for genetic testing among patients with IBC was found to reflect the expected rate from the NCCN 10 and institutional guidelines for referral in patients with breast cancer. There were significant associations noted between referral for genetic testing and a family history of breast cancer (P 5 .0025) and ovarian cancer (P 5 .0094). Similarly, an age of 45 years was found to be significantly associated with referral for genetic testing (P < .0001) (see Supporting Information Table 1B ). However, it is difficult to draw conclusions from these results due to the highly selective nature of the current study sample, especially because the presence of a family history is part of our institutional criteria for referral to genetic counseling.
To our knowledge, the current study uniquely describes the rate of BRCA pathogenic variants among patients with IBC. These results suggest that the role played by BRCA pathogenic variants in the development of IBC tumors may be similar to the role of these variants in other types of breast cancer. The results of the current study confirm that patients diagnosed with IBC may undergo testing based on testing guidelines, because we found no significant difference in the BRCA positivity rate between patients with and without IBC. The current study results also suggested that carriers of BRCA pathogenic variants with breast cancer may develop IBC at an earlier age compared with non-IBC patients. Therefore, given that genetic testing already is warranted for younger patients and those with a family history of breast cancer and/or ovarian cancer, testing should continue to be made available to those who meet current clinical testing criteria from the NCCN.
